4//SEC Filing
Sard Mark 4
Accession 0001104659-20-071839
CIK 0001264587other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 11:22 AM ET
Size
5.1 KB
Accession
0001104659-20-071839
Insider Transaction Report
Form 4
Sard Mark
Director
Transactions
- Disposition from Tender
Common Stock
2020-06-10−51,468→ 0 total
Footnotes (1)
- [F1]Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
Documents
Issuer
STEMLINE THERAPEUTICS INC
CIK 0001264587
Entity typeother
Related Parties
1- filerCIK 0001737651
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 11:22 AM ET
- Size
- 5.1 KB